Protagenic Therapeutics Seeks Auditor Ratification Amid Going Concern Doubts

TL;DR

**PTIXW is swapping auditors and facing 'going concern' issues, signaling deep financial trouble; steer clear until they prove viability.**

AI Summary

Protagenic Therapeutics, Inc. (PTIXW) is holding its Annual Meeting of Stockholders on December 31, 2025, virtually, to ratify the appointment of Green Growth CPAs as its independent registered public accounting firm for the fiscal year ending March 31, 2026. This follows the dismissal of MaloneBailey LLP on August 7, 2025. MaloneBailey's report for the fiscal year ended December 31, 2024, included an explanatory paragraph citing substantial doubt about the Company's ability to continue as a going concern. The Board of Directors also approved a change in the Company's fiscal year-end from December 31 to March 31, effective August 7, 2025. The Company's principal executive office is located at 149 Fifth Avenue, Suite 500, New York, NY 10010. Stockholders of record as of December 9, 2025, are entitled to vote.

Why It Matters

This DEF 14A filing is crucial for investors as it highlights a change in Protagenic Therapeutics' independent auditor, Green Growth CPAs, following the dismissal of MaloneBailey LLP. The previous auditor's 'going concern' qualification for the fiscal year ended December 31, 2024, signals significant financial instability, which could impact investor confidence and the company's ability to secure future financing. The shift to a virtual annual meeting on December 31, 2025, also reflects a modern approach to shareholder engagement, but the underlying financial health remains a primary concern, especially in a competitive biotech landscape where funding is paramount.

Risk Assessment

Risk Level: high — The filing explicitly states that MaloneBailey LLP's report for the fiscal year ended December 31, 2024, contained an explanatory paragraph regarding "substantial doubt about the Company’s ability to continue as a going concern." This is a critical red flag indicating severe financial instability and a high risk of business failure.

Analyst Insight

Investors should exercise extreme caution and consider divesting from PTIXW given the explicit 'going concern' warning from its former auditor. A thorough review of the company's latest 10-K and 10-Q filings, specifically the 'Risk Factors' and 'Management’s Discussion and Analysis of Financial Condition and Results of Operations' sections, is imperative before making any investment decisions.

Key Numbers

• December 31, 2025 — Annual Meeting Date (Date of the virtual Annual Meeting of Stockholders)
• December 9, 2025 — Record Date (Date for determining stockholders entitled to vote at the Meeting)
• August 7, 2025 — Auditor Dismissal Date (Date MaloneBailey LLP was dismissed and Green Growth CPAs was engaged)
• March 31, 2026 — New Fiscal Year End (New fiscal year end for which Green Growth CPAs will audit financial statements)
• December 31, 2024 — Former Fiscal Year End (Fiscal year for which MaloneBailey LLP issued a 'going concern' opinion)

Key Players & Entities

• Protagenic Therapeutics, Inc. (company) — Registrant
• Green Growth CPAs (company) — New independent registered public accounting firm
• MaloneBailey LLP (company) — Former independent registered public accounting firm, dismissed on August 7, 2025
• Garo H. Armen (person) — Chairman of Protagenic Therapeutics, Inc.
• Securities and Exchange Commission (regulator) — Federal securities regulator
• Equiniti Trust Company, LLC (company) — Transfer agent and inspector of election
• The Nasdaq Capital Market (company) — Stock exchange where PTIXW aims to meet listing requirements
• 149 Fifth Avenue, Suite 500, New York, NY 10010 (company) — Principal executive office of Protagenic Therapeutics, Inc.

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: Malone Bailey LLP's report for the fiscal year ended December 31, 2024, included an explanatory paragraph citing substantial doubt about the Company's ability to continue as a going concern. This indicates significant financial instability and potential future operational challenges.
• Auditor Change [medium — regulatory]: The company dismissed Malone Bailey LLP on August 7, 2025, and appointed Green Growth CPAs. This change, especially following a going concern opinion, may raise questions about the previous auditor's findings and the company's financial reporting integrity.
• Fiscal Year End Change [medium — operational]: The company changed its fiscal year-end from December 31 to March 31, effective August 7, 2025. This shift can complicate year-over-year comparisons and may indicate a need to restructure financial reporting or operations.
• Nasdaq Listing Requirements [high — market]: Forward-looking statements mention the company's ability to meet the continued listing requirements of The Nasdaq Capital Market. Failure to meet these requirements could lead to delisting, significantly impacting liquidity and investor confidence.
• Need for Additional Financing [high — financial]: The company anticipates future capital-raising activities and acknowledges the need for additional financing. Uncertainty in obtaining this financing could impede operations, research and development, and overall business growth.
• Clinical Trial Success [high — operational]: Forward-looking statements reference the company's success with clinical trials. Clinical trial outcomes are inherently uncertain and can significantly impact the company's future prospects and valuation.
• Key Personnel Retention [medium — operational]: The company's ability to recruit or retain key personnel and executive officers is cited as a risk. Loss of critical talent can disrupt operations, research, and strategic execution.

Industry Context

Protagenic Therapeutics operates in the biotechnology sector, a highly competitive and capital-intensive industry. Success is heavily dependent on research and development, clinical trial outcomes, and the ability to secure significant funding. The industry faces stringent regulatory hurdles and a long product development cycle, making it prone to high failure rates and significant financial risks.

Regulatory Implications

The change in auditors, particularly following a going concern opinion, may attract increased scrutiny from regulatory bodies like the SEC. The company must ensure robust financial reporting and compliance with Nasdaq listing requirements to avoid delisting. Any missteps in financial disclosures or operational execution could lead to further regulatory challenges.

What Investors Should Do

1. Review the 'Risk Factors' section thoroughly, paying close attention to the going concern, financing needs, and clinical trial risks.
2. Understand the implications of the fiscal year-end change on financial reporting and comparability.
3. Monitor the company's ability to secure future financing and meet Nasdaq listing requirements.
4. Evaluate the rationale behind the auditor change and the qualifications of the new auditor, Green Growth CPAs.

Key Dates

• 2025-12-31: Annual Meeting of Stockholders — This is the date for the virtual meeting where stockholders will vote on the ratification of the appointment of Green Growth CPAs as the independent registered public accounting firm.
• 2025-12-09: Record Date — Stockholders of record on this date are entitled to vote at the Annual Meeting, determining who has voting rights.
• 2025-08-07: Auditor Dismissal and Fiscal Year Change — Malone Bailey LLP was dismissed, and Green Growth CPAs was engaged. Simultaneously, the company changed its fiscal year-end to March 31. This indicates significant changes in financial oversight and reporting structure.
• 2024-12-31: Former Fiscal Year End — The fiscal year for which Malone Bailey LLP issued a 'going concern' opinion, highlighting significant financial risks.
• 2026-03-31: New Fiscal Year End — The new fiscal year end for which Green Growth CPAs will audit the financial statements, reflecting the company's adjusted reporting cycle.

Glossary

DEF 14A

A proxy statement filing required by the U.S. Securities and Exchange Commission (SEC) for companies holding annual meetings of shareholders. It provides detailed information about matters to be voted on, including director elections, executive compensation, and auditor appointments. (This document is the primary source of information for the annual meeting and contains details about the company's governance, financial reporting, and strategic decisions.)

Going Concern

An accounting term indicating that a company is expected to continue operating for the foreseeable future. A 'substantial doubt about a company's ability to continue as a going concern' means there are significant uncertainties that could prevent the company from meeting its obligations. (The mention of 'going concern' by the previous auditor is a critical red flag regarding the company's financial health and long-term viability.)

Proxy Statement

A document that the SEC requires companies to provide to shareholders before their annual meeting. It contains information about the company's board of directors, executive compensation, and the proposals to be voted on. (This is the specific type of filing being analyzed, detailing the agenda and supporting information for the upcoming shareholder meeting.)

Independent Registered Public Accounting Firm

An external accounting firm hired by a company to audit its financial statements. They must be independent of the company to ensure an unbiased opinion on the fairness of the financial reporting. (The ratification of Green Growth CPAs as the new auditor is the primary purpose of the annual meeting described in this filing.)

Fiscal Year

A period of 12 months used by a company for accounting and financial reporting purposes. It does not necessarily align with the calendar year. (The company has changed its fiscal year-end from December 31 to March 31, impacting the timing and structure of its financial reporting.)

Forward-Looking Statements

Statements in a filing that predict or describe future events or conditions. These are subject to risks and uncertainties, and actual results may differ materially. (The filing includes a cautionary statement about forward-looking statements, highlighting the inherent uncertainties in the company's future performance and operations.)

Year-Over-Year Comparison

This DEF 14A filing focuses on the upcoming annual meeting and auditor ratification, rather than a comprehensive financial performance review compared to a prior period. However, the context provided by the previous 10-K (filed March 31, 2025, for the year ended December 31, 2024) highlights a significant 'going concern' issue. The change in fiscal year-end and auditor also indicates a shift in the company's financial reporting and oversight structure since the last annual reporting cycle.

Key Financial Figures

• $0 — December 31, 2024 and 2023, there were $0 and $0, respectively Audit Committee

Filing Documents

• formdef14a.htm (DEF 14A) — 196KB
• 0001493152-25-026414.txt ( ) — 197KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 15 ADDITIONAL INFORMATION 16 OTHER MATTERS 16 WHERE YOU CAN FIND MORE INFORMATION 16 2 CAUTIONARY The and expected use of proceeds therefrom, our estimates regarding expenses, future revenues, capital requirements, needs for additional financing, our ability to obtain additional financing, our success with regard to any clinical trials, our ability to recruit or retain key personnel or to retain our executive officers, our stock price and ability to meet the continued listing requirements of The Nasdaq Capital Market, and any other statements regarding our future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts, are forward-looking statements within the meaning of the federal securities laws. These statements are subject to numerous risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from the results expressed or implied by the statements. We describe risks and uncertainties that could cause actual results and events to differ materially in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Annual Report”), which was filed on March 31, 2025, and as revised or supplemented by our most recent Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025, which was filed on May 13, 2025. Any forward-looking statements should be considered in light of such important factors. We undertake no obligation to revise or update publicly any forward-looking statemen

View Full Filing

View this DEF 14A filing on SEC EDGAR